Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX43 in previously treated advanced non-small cell lung cancer
2025-523803-31-00Phase 2Authorised
- Sponsor
- Henlius
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 10
01
Overview
Phase 2, open-label, single-arm trial of HLX43 in non-small cell lung cancer (NSCLC), sponsored by Henlius. Primary endpoint: Objective response rate. Planned start Mar 2026; status: authorised.
02
Drugs
HLX43
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-523803-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523803-31-00.